A Phase I, Multi-center, Multi-part Study to Investigate Safety, Tolerability, PK, PD, and Immunogenicity of RO7669330 Intravitreal Injections in Participants With GA Secondary to AMD: Part 1A: Open-label, MAD; Part 1B: Randomized PD Pilot; Part 2: Masked, Randomized, Active-comparator-controlled

The main purpose of this study is to assess the ocular and systemic safety and tolerability of RO7669330 in GA secondary to AMD after multiple unilateral intravitreal (IVT) doses.

Start Date16 Jul 2025

Sponsor / Collaborator

Roche Holding AG

NCT06970665

/ RecruitingPhase 4

A Phase 3/4, Multicenter, Single-arm Clinical Study to Assess the Safety of Intravitreal Administration of ASP3021 in Participants in Japan With Geographic Atrophy Secondary to Age-related Macular Degeneration

Age-related macular degeneration (AMD) is an eye disease which causes people to lose their vision over time. AMD damages the macula, which is in the middle of the retina - the light sensitive part at the back of the eye. In AMD, the cells in the macula die over time, usually over several years, leading to vision loss. When AMD gets worse, it can turn into either geographic atrophy (GA), neovascular AMD, or both.
This study is for people in Japan of 40 years of age or older, who have geographic atrophy.
The main aim of this study is to collect information about the safety of ASP3021 and how well people tolerate treatment with ASP3021.
During the study, people will receive monthly injections of ASP3021 for 12 months. ASP3021 is given by injection into the affected eye. This procedure is called an intravitreal injection.
People will be in the study for about 1 year. People will visit their study clinic several times for health checks.

Start Date08 Jul 2025

Sponsor / Collaborator

Astellas Pharma, Inc.

NCT06779773

/ RecruitingNot Applicable

A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY™) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration

This study is for people who have geographic atrophy due to age-related macular degeneration (AMD). AMD happens when the macula, the light-sensitive layer at the back of the eye called the retina, becomes damaged and causes a person's central vision to worsen. Geographic atrophy is an advanced form of AMD where cells in the retina waste away and die. Over time this can lead to permanent loss of vision.
Avacincaptad pegol can help slow down the worsening or progression of geographic atrophy. Avacincaptad pegol is a treatment approved in the US to treat geographic atrophy.
This study is about collecting information on how people with geographic atrophy are treated in routine clinical practice. This includes recording any medical problems from avacincaptad pegol. This is known as an observational study. Information will be collected from the peoples' medical records during and after treatment. The people in this study will have geographic atrophy in 1 or both eyes and they and their doctor has decided they will be treated with avacincaptad pegol. The individual's doctor decides on treatment, not the study sponsor (Astellas).
People that want to take part in the study will have eye examinations that they would usually have as part of their routine care. People will also be asked to complete surveys about their eye health. These surveys will occur when treatment starts and then every 6 months for the first 2 years. After 2 years the surveys will happen once a year. The people on the study can take part if their doctor provides treatment with avacincaptad pegol and they want to continue with the study. The people on the study can take part for up to 3 years or up to 5 years, depending on when they start the study.

Start Date22 Jan 2025

Sponsor / Collaborator

Astellas Pharma Global Development, Inc.

100 Clinical Results associated with Avacincaptad pegol

100 Translational Medicine associated with Avacincaptad pegol

100 Patents (Medical) associated with Avacincaptad pegol

Literatures (Medical) associated with Avacincaptad pegol

01 Sep 2025·RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES

SILICONE OIL MICRODROPLETS FROM SYRINGES WITH INTRAVITREAL ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR AND COMPLEMENT INHIBITOR INJECTIONS

Article

Author: Wei, Libby ; Thompson, John T. ; Fan, Xiaoxuan ; Lee, Erica

Purpose::

To quantify the amount of silicone oil in intravitreal anti–vascular endothelial growth factor and complement inhibitor injections in prefilled and commercial syringes (silicone-lubricated and silicone-free).

Methods::

Patients deemed clinically appropriate to receive one of five intravitreal medications received the recommended dose. Syringes were overfilled such that 0.01-0.04 mL remained after injection for analysis. Aflibercept and ranibizumab were available in prefilled syringes. Pegcetacoplan, faricimab, and avacincaptad pegol were prepared with Becton Dickinson polycarbonate (BD) syringes. Faricimab was also prepared in Ocuject VitreJect (OV) silicone-free syringes. Samples were analyzed using spectral flow cytometry.

Results::

Silicone oil was found in all syringes. The lowest amounts of silicone oil were found in the Mili-Q water in OV syringes (4.02 ± 0.3 particles per microliter) and ranibizumab 0.5 mg prefilled syringes (8.33 ± 3.1). Intermediate levels of silicone oil were detected in aflibercept prefilled syringes (35.5 ± 21.8) and faricimab in OV syringes (74.6 ± 10.1), significantly greater than Mili-Q water in OV syringes and ranibizumab. Significantly higher levels of silicone oil were found with faricimab (324.9 ± 30), pegcetacoplan (378.1 ± 379.6), and avacincaptad pegol (113.5 ± 14) in BD syringes than the low or intermediate groups. The filter needles used to draw up medications from vials likely contributed to the amount of silicone oil detected in the samples.

Conclusion::

Commonly used BD polycarbonate syringes for intravitreal injections caused significantly higher levels of silicone oil to be injected into the eye than prefilled or silicone-free syringes. Repeated injections with more viscous intravitreal drugs increase the amount of silicone oil in the vitreous, leading to symptomatic floaters.

01 Aug 2025·AMERICAN JOURNAL OF OPHTHALMOLOGY

Ocular Adverse Events Associated with Pegcetacoplan and Avacincaptad Pegol for Geographic Atrophy: A Population-Based Pharmacovigilance Study

Article

Author: Kertes, Peter J ; Muni, Rajeev H ; Popovic, Marko M ; Mihalache, Andrew ; Kailani, Zeena

OBJECTIVE:

To evaluate the postmarketing ocular adverse events (AEs) reported for avacincaptad pegol and pegcetacoplan, the only Food and Drug Administration (FDA)-approved treatments for geographic atrophy (GA).

DESIGN:

Retrospective pharmacovigilance analysis.

SUBJECTS:

Ocular AE reports in the FDA Adverse Event Reporting System (FAERS) in which pegcetacoplan or avacincaptad pegol was identified as the primary suspect drug were analyzed.

METHODS:

Using the OpenVigil 2.1 data mining software, we conducted a retrospective pharmacovigilance analysis of the FAERS database from inception to December 2024. We conducted disproportionality analyses to assess reporting odds ratios (RORs) for specific drug-AE combinations compared with all other drugs in the database.

MAIN OUTCOME MEASURES:

Ocular AEs were evaluated.

RESULTS:

A total of 752 and 80 patients with AEs secondary to pegcetacoplan and avacincaptad pegol, respectively, were identified. Ocular AEs disproportionately overreported for pegcetacoplan included anterior segment (iris) hemorrhage (ROR 1767, 95% CI 538-5803), iris neovascularization (ROR 1248, 95% CI 502-3099), choroidal neovascularization (ROR 1328, 95% CI 956-1845), intraocular injection complication (ROR 2552, 95% CI 1607-4053), hemorrhagic occlusive retinal vasculitis (ROR 4606, 95% CI 2000-10,611), retinal occlusive vasculitis (ROR 2352, 95% CI 1313-4212), and bacterial endophthalmitis (ROR 1260, 95% CI 613-2589). Ocular AEs disproportionately overreported for avacincaptad pegol included choroidal neovascularization (ROR 1169, 95% CI 426-3205), vitritis (ROR 782, 95% CI 316-1936), dry age-related macular degeneration (ROR 684, 95% CI 316-1936), and cystoid macular edema (ROR 445, 95% CI 140-1412).

CONCLUSIONS:

Current prescribing patterns indicate that a broader spectrum of ocular AEs were reported for pegcetacoplan than avacincaptad pegol. These findings aim to enhance clinicians' understanding of the safety profiles of these agents, enabling informed patient care and heightened vigilance of these novel GA treatments.

01 Jun 2025·Ophthalmology and Therapy

Clinical Outcomes of Treatment of Geographic Atrophy: A Narrative Review

Review

Author: Torp, Thomas Lee ; Vergmann, Anna Stage ; Nissen, Anne Helene Køllund

RATIONALE:

In 2023, the U.S. Food and Drug Administration approved pegcetacoplan (SYFOVRE) as the first therapeutic option for geographic atrophy (GA), a previously untreatable condition associated with age-related macular degeneration. Following this, avacincaptad pegol (Izervay) was also approved for GA treatment, further expanding therapeutic options.

OBJECTIVES:

This article aims to give an overview of the clinical outcomes of GA treatment and to discuss which patient groups may benefit most from these therapies.

METHODS:

A review of the literature was conducted using the databases PubMed, Cochrane Library, and ClinicalTrials.gov. The search yielded six relevant studies.

CONCLUSIONS:

The management of geographic atrophy has advanced with therapies like pegcetacoplan and avacincaptad pegol showing clear benefits in slowing lesion growth. However, safety concerns, such as neovascular complications, persist. Photobiomodulation and dietary supplementation provide alternative options with modest benefits, particularly in the early stages. Larger studies are needed to confirm long-term safety, efficacy, and optimal treatment strategies.

146

News (Medical) associated with Avacincaptad pegol

08 Oct 2025

·www.prnewswire.com

Astellas to Present New Data on IZERVAY™ (avacincaptad pegol intravitreal solution) in Geographic Atrophy at AAO 2025 Annual Meeting

Presentations include long-term GATHER2 open-label extension data, real-world treatment patterns on safety, and biomarker insights on geographic atrophy disease progression TOKYO, Oct. 8, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced new data for IZERVAY™ (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) will be highlighted at the upcoming American Academy of Ophthalmology Annual Meeting (AAO 2025), October 18-20, in Orlando, Fla. The data feature long-term safety and efficacy results from the GATHER2 open-label extension study, real-world evidence on treatment patterns and safety of IZERVAY in the U.S., and the latest findings on a structure-function link in GA via ellipsoid zone integrity and low-luminance deficit. Marci English, Senior Vice President, Biopharma and Ophthalmology Development, Astellas Pharma "Astellas continues to advance understanding of geographic atrophy (GA) through new data that deepen insights into disease progression and treatment. We are committed to partnering with the retina community to continue driving innovation that improves outcomes for patients with GA." Overview of Astellas Presentations at AAO 2025 IZERVAY is approved for the treatment of GA in the United States and Japan, and remains investigational in other countries and regions. About IZERVAY™ (avacincaptad pegol intravitreal solution) IMPORTANT SAFETY INFORMATION AND USE Do NOT receive IZERVAY if you: Have an infection in or around your eye Have active swelling in or around your eye that may include pain and redness IZERVAY can cause serious side effects: Eye injections like the one for IZERVAY can cause an eye infection (endophthalmitis) or separation of layers of the retina (retinal detachment). Call your healthcare provider right away if you have redness of the eye, eye pain, increased discomfort, worsening eye redness, blurred or decreased vision, an increased number of small specks floating in your vision, flashes of light, or increased sensitivity to light. There is a risk of developing wet AMD with IZERVAY. You should report any symptoms (visual distortions such as straight lines seeming bent, deterioration in vision, dark spots, loss of central vision) to your healthcare provider to monitor. IZERVAY may cause a temporary increase in eye pressure after the injection. Your healthcare provider will monitor this after each injection. Before receiving IZERVAY tell your healthcare provider about all of your medical conditions including if you: Have a history of seeing flashes of light or small specks floating in your vision and if you have a sudden increase of size and number of these specks. Have high pressure in the eye or if you have glaucoma. Are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine. Are taking any medications, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Tell your healthcare provider about any medicine you take. What should I avoid while receiving IZERVAY? Your vision may be impaired after receiving an eye injection or after an eye exam. Do not drive or use machinery until your vision has recovered sufficiently. What are the most common side effects of IZERVAY? Blood in the white of the eye Increase in eye pressure Blurred vision Wet age-related macular degeneration These are not all the possible side effects of IZERVAY. Tell your healthcare provider about any side effect that bothers you or that does not go away. Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit , or call 1-800-FDA-1088. Please see full Prescribing Information for more information. What is IZERVAY™? IZERVAY (avacincaptad pegol intravitreal solution) is a prescription eye injection, used to treat geographic atrophy (GA), the advanced form of dry age-related macular degeneration (AMD). About Geographic Atrophy Age-related macular degeneration (AMD) is the major cause of moderate and severe loss of central vision in aging adults, affecting both eyes in the majority of patients. The macula is a small area in the central portion of the retina responsible for central vision. As AMD progresses, the loss of retinal cells and the underlying blood vessels in the macula results in marked thinning and/or atrophy of retinal tissue. Geographic atrophy, associated with AMD, leads to further irreversible loss of vision in these patients. About the GATHER Clinical Trials IZERVAY met its primary endpoint in the GATHER1 (NCT02686658) clinical trial and the GATHER2 (NCT04435366) clinical trial, both of which were randomized, double-masked, sham-controlled, multicenter Phase 3 clinical trials. These trials evaluated the safety and efficacy of monthly 2 mg intravitreal administration of IZERVAY in patients with GA secondary to AMD. For the first 12 months in both trials, patients were randomized to receive either IZERVAY 2 mg or sham monthly. There were 286 participants enrolled in GATHER1 and 448 participants enrolled in GATHER2. The primary efficacy endpoints in both pivotal studies were based on GA area measured by fundus autofluorescence at three time points: baseline, month 6, and month 12. Safety was evaluated in over 700 patients with GA across the two trials. In year 2 of the GATHER2 study, patients treated with IZERVAY in year 1 were re-randomized to receive either IZERVAY dosed monthly (EM, n=96) or every other month (EOM, n=93); patients who received sham in year 1 continued to receive sham in year 2 (n=203). About Astellas Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Learn more at . Cautionary Notes In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice. SOURCE Astellas Pharma Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultPhase 3Drug Approval

19 Sep 2025

·www.astellas.com

Astellas Receives Conditional Approval for IZERVAY, making it the first and only approved treatment for the Suppression of Geographic Atrophy Growth in Japan

TOKYO, Sep 19, 2025 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted Conditional Approval of IZERVAY (avacincaptad pegol intravitreal solution: ACP) for the suppression of geographic atrophy (GA) growth in atrophic age-related macular degeneration (AMD). This approval – achieved in just seven months through an expedited pathway designed to bring innovative treatments to patients with serious unmet need – makes ACP the first and only approved treatment for patients living with GA in Japan. In the global GATHER1 and GATHER2 clinical trials, ACP met its primary endpoint by significantly reducing the rate of GA lesion growth compared with sham.1,2 The mean rate of GA lesion growth reduction over 12 months was 35% in GATHER1 and 18% in GATHER2.3 Sustained efficacy was observed over two years of follow-up, with efficacy observed as early as six months following the first injection.1,2,4 ACP was consistently well tolerated across both the trials, with less than 2% of participants stopping treatment due to adverse events.1,2 Marci English, Senior Vice President, Biopharma and Ophthalmology Development, Astellas“This approval highlights the strength of the GATHER clinical program and the value of continued innovation in ophthalmology. Under the Conditional Approval system, we will build on these findings with confirmatory studies to further strengthen the evidence base and expand understanding of how to best help people living with geographic atrophy.” GA is an advanced and irreversible form of age-related macular degeneration that causes progressive vision loss.5 In Japan, GA is estimated to affect nearly 100,000 people.6,7 Without timely treatment, an estimated 66% of people with GA become legally blind or severely visually impaired – a devastating reality that destroys independence and wellbeing.8,9 ACP, a complement C5 inhibitor, significantly slowed the growth of GA lesions, which is expected to slow visual impairment by reducing activation of the complement system, which drives retinal cell degeneration.3,10 Astellas will now work with the relevant authorities to enable patient access to ACP as quickly as possible. The Company has already reflected the impact of this approval in its financial forecast of the current fiscal year ending March 31, 2026. About avacincaptad pegol (ACP)ACP is a synthetic aptamer that inhibits the complement C5 protein.10 Overactivity of the complement system and the C5 protein play a critical role in the development and growth of scarring and vision loss associated with GA secondary to AMD.10 By targeting C5, ACP is considered to decrease activity of the complement system known to cause the degeneration of retinal cells and thus slow the progression of GA.10 About Geographic Atrophy (GA)GA is an advanced form of age-related macular degeneration (AMD) that leads to irreversible and progressive vision loss.8,10,11 It affects the macula, the central portion of the retina responsible for central vision. AMD is the leading cause of visual loss in people aged over 50 years old in developed countries.2 In Japan, an estimated 100,000 people live with GA, and no approved treatments have been available until now.6,7 About the GATHER Clinical Trial ProgramIZERVAY met its primary endpoint in the GATHER1 (NCT02686658) clinical trial and the GATHER2 (NCT04435366) clinical trial, both of which were randomized, double-masked, sham-controlled, multicenter Phase 3 clinical trials. These trials evaluated the safety and efficacy of monthly 2 mg intravitreal administration of IZERVAY in patients with GA secondary to AMD. For the first 12 months in both trials, patients were randomized to receive either IZERVAY 2 mg or sham monthly. There were 286 participants enrolled in GATHER1, and 448 participants enrolled in GATHER2. The primary efficacy endpoints in both pivotal studies were based on GA area measured by fundus autofluorescence at three time points: baseline, month 6, and month 12. Safety was evaluated in over 700 patients with GA across the two trials. About AstellasAstellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Learn more at www.astellas.com. Cautionary NotesIn this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas’ intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice. References Click below for a copy of the full press release

Clinical ResultPhase 3Drug Approval

30 Jul 2025

·www.astellas.com

Posted Financial Results for Q1 YTD/FY2025

Jul 30, 2025IR Posted Financial Results for Q1 YTD/FY2025 Jul 17, 2025Press Releases Astellas Announces a Partnership with the “Korea Institute of Startup and Entrepreneurship Development”, an Umbrella Organization of a Korean Government Agency, for the Operation of the“Partnership with Global Companies Program” Jul 10, 2025Press Releases Sales of IZERVAY™ (Preliminary Figures)

Financial Statement

100 Deals associated with Avacincaptad pegol

External Link

KEGG	Wiki	ATC	Drug Bank
D11748	-	-	DB15165

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Geographic Atrophy	United States	Astellas Pharma US, Inc.	04 Aug 2023

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Age Related Macular Degeneration	NDA/BLA	Canada	Astellas Pharma Canada, Inc.	01 Feb 2025
dry age-related macular degeneration	Phase 3	United States	IVERIC bio, Inc.	22 Jun 2020
dry age-related macular degeneration	Phase 3	Argentina	IVERIC bio, Inc.	22 Jun 2020
dry age-related macular degeneration	Phase 3	Australia	IVERIC bio, Inc.	22 Jun 2020
dry age-related macular degeneration	Phase 3	Austria	IVERIC bio, Inc.	22 Jun 2020
dry age-related macular degeneration	Phase 3	Belgium	IVERIC bio, Inc.	22 Jun 2020
dry age-related macular degeneration	Phase 3	Brazil	IVERIC bio, Inc.	22 Jun 2020
dry age-related macular degeneration	Phase 3	Canada	IVERIC bio, Inc.	22 Jun 2020
dry age-related macular degeneration	Phase 3	Colombia	IVERIC bio, Inc.	22 Jun 2020
dry age-related macular degeneration	Phase 3	Croatia	IVERIC bio, Inc.	22 Jun 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EURETINA2025	Not Applicable	Geographic Atrophy	19,331	avacincaptad pegol (ACP)	dccitrptfc(upnwjksndp) = ndawlukuvo tiezcymakp (nlbiqlbtfg ) View more	Positive	04 Sep 2025
				pegcetacoplan (PEG)	dccitrptfc(upnwjksndp) = vclmhyiuuu tiezcymakp (nlbiqlbtfg ) View more
EURETINA2025	Not Applicable	Age Related Macular Degeneration	22	Pegcetacoplan 15mg monthly	ivhaovqova(fkyeisyodx) = High-certainty evidence indicates that PEG or ACP do not confer significant benefit to low-luminance BCVA. nlrfgnqxqt (msmspzemjl )	Negative	04 Sep 2025
				Pegcetacoplan 15mg every other month
NCT02686658 \| NCT04435366 (GATHER2, EURETINA2024) Manual	Phase 2/3	Geographic Atrophy	-	Avacincaptad Pegol 2 mg	cppgukytnk(yogoawopzp) = tusvdgshlv qnfvkwrmxv (sqrqucyywx )	Positive	19 Sep 2024
NCT04435366 (GATHER2, PRNewswire) Manual	Phase 3	Age Related Macular Degeneration	-	IZERVAY	jldxvihujx(tsapoaomxh) = IZERVAY was well tolerated over 2 years, with one case each of non-serious intraocular inflammation (IOI) and culture-positive endophthalmitis. There were no cases of ischemic neuropathy or retinal vasculitis. isozpbrbni (cnhorofhpl ) View more	Positive	04 Nov 2023
				IZERVAY
EURETINA2023	Not Applicable	-	-	Avacincaptad pegol 2 mg	jeshkzjxcn(gqwngnmuou) = ebhzumcbsj ufjdwjtlvf (lnjroaeqbg ) View more	-	05 Oct 2023
EURETINA2023	Not Applicable	Geographic Atrophy	-	Avacincaptad pegol 2 mg	ulwgwstdzr(oxwtvjlwjz) = qkjwcvngpa gskegjcjsl (oqskcjvvgd, 0.56 - 0.15-2.06)	-	05 Oct 2023
NCT02686658 \| NCT04435366 (GATHER2, FDA) Manual	Phase 2/3	Geographic Atrophy	624	IZERVAY (GATHER1)	sziliwfkgk(vgbhdzolaz) = dokqvhzbaz wltlwarrtd (kxrlrnbbhn )	Positive	04 Aug 2023
				Sham (GATHER1)	sziliwfkgk(vgbhdzolaz) = ojsymsvtfe wltlwarrtd (kxrlrnbbhn )
NCT05571267 (CTgov)	Phase 2	Wet age-related macular degeneration	1	Avastin (Zimura and Avastin)	liltyoydkd = djqpkjkyrn qtvlsmnkgz (mezccmfzun, fpfqjhelbn - opjuxwxshz) View more	-	03 Apr 2023
				Zimura+Lucentis (Zimura and Lucentis)	firlskhssa(afodfmoiqr) = toqaadevuk gomtvrlhyr (jkilexsioi, ktqdsgkbvq - builcdbweq) View more
NCT04435366 (GATHER2, Corporate Publications) Manual	Phase 3	Geographic Atrophy	447	Avacincaptad pegol	zcjadxfesh(ftpwajnbfq) = bpnjysrjdy bbxzjslfcm (uqqblozdrp ) View more	Positive	06 Sep 2022
				Sham	zcjadxfesh(ftpwajnbfq) = okdxvmogcv bbxzjslfcm (uqqblozdrp ) View more
NCT02686658 (GATHER1, ARVO2022)	Phase 2/3	Geographic Atrophy	-	Avacincaptad pegol 2 mg	gkwurdrcng(cfbngoehjb) = ctbsqdlywx btojfcxshm (ptkmhrsoiu )	-	01 May 2022
				avacincaptad pegol (Sham)	gkwurdrcng(cfbngoehjb) = obxvyhqnxb btojfcxshm (ptkmhrsoiu )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis